| 000 | 00851 a2200241 4500 | ||
|---|---|---|---|
| 005 | 20250513140022.0 | ||
| 264 | 0 | _c19980317 | |
| 008 | 199803s 0 0 eng d | ||
| 022 | _a0036-8075 | ||
| 024 | 7 |
_a10.1126/science.279.5354.1113b _2doi |
|
| 040 |
_aNLM _beng _cNLM |
||
| 100 | 1 | _aKorn, D | |
| 245 | 0 | 0 |
_aFDA reform: unintended outcome? _h[electronic resource] |
| 260 |
_bScience (New York, N.Y.) _cFeb 1998 |
||
| 300 |
_a1113 p. _bdigital |
||
| 500 | _aPublication Type: Comment; Letter | ||
| 650 | 0 | 4 | _aBiological Products |
| 650 | 0 | 4 | _aResearch |
| 650 | 0 | 4 | _aUnited States |
| 650 | 0 | 4 |
_aUnited States Food and Drug Administration _xlegislation & jurisprudence |
| 773 | 0 |
_tScience (New York, N.Y.) _gvol. 279 _gno. 5354 _gp. 1113 |
|
| 856 | 4 | 0 |
_uhttps://doi.org/10.1126/science.279.5354.1113b _zAvailable from publisher's website |
| 999 |
_c9476496 _d9476496 |
||